“Strategic review” after the share price has risen 13%

Share post:
Share post.

InterMail has announced that it has initiated a “strategic review” and engaged an advisor to assist them. It comes after the share price last week rose 13%.

InterMail: Ticker: IMAIL | Price: DKK 16,50 | Market Cap.: DKK 58M | YTD: 34%

The strategic review will clarify how InterMail can best position itself for the changes in the markets, which include extensive consolidation and a shift towards strong Nordic communications houses. InterMail also has an acquisitive growth strategy, and as the company grows on a Scandinavian level and significantly improves its earnings and cash flow, the company itself also becomes an increasingly interesting acquisition candidate for, among others, Nordic media houses.

The strategic review is fully in line with our investment case, which can be read here.

Disclaimer

Selected cases

CS Medica
Look here
Ekobot
Look here
Biosergen
Look here
Nexcom
Look here
Curasight
Look here
Mdundo
Look here
Previous slide
Next slide

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.




Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Selected cases

CS Medica
Look here
Ekobot
Look here
Biosergen
Look here
Nexcom
Look here
Curasight
Look here
Mdundo
Look here

Most read cases

Company cases

Market cases

Sector Cases

Back to investment cases

Kapital Partner A/S

Ewaldsgade 9

2200 København N
CVR: 37364843

Privatlivspolitik  –  Cookies

Skriv til os

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email